Diabetes and Antiplatelet Therapy in Acute Coronary Syndrome
- 22 February 2011
- journal article
- review article
- Published by Wolters Kluwer Health in Circulation
- Vol. 123 (7) , 798-813
Abstract
No abstract availableThis publication has 175 references indexed in Scilit:
- Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trialsThe Lancet, 2009
- Clinical overview of promising nonthienopyridine antiplatelet agentsAmerican Heart Journal, 2008
- Pharmacology of emerging novel platelet inhibitorsAmerican Heart Journal, 2008
- Effects of Intensive Glucose Lowering in Type 2 DiabetesNew England Journal of Medicine, 2008
- Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary interventionAmerican Heart Journal, 2008
- Peroxisome proliferator-activated receptor-γ agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery diseaseAmerican Heart Journal, 2004
- Insulin-induced expression of prostacyclin receptors on platelets is mediated through ADP-ribosylation of Giα proteinLife Sciences, 1998
- Thromboxane Biosynthesis and Platelet Function in Type II Diabetes MellitusNew England Journal of Medicine, 1990
- Aspirin, Heparin, or Both to Treat Acute Unstable AnginaNew England Journal of Medicine, 1988
- Protective Effects of Aspirin against Acute Myocardial Infarction and Death in Men with Unstable AnginaNew England Journal of Medicine, 1983